Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
Nutriband Inc. (NASDAQ:NTRB) reported strong Q3 2024 financial results, with record revenue of $645,796, up 50.94% year-over-year. The company maintains a solid cash position of $5.7 million, with total assets of $12.55 million and stockholders' equity of $11.23 million.
Through its Pocono Pharma subsidiary, Nutriband is expanding its kinesiology tape manufacturing services, with products available in major retailers like Target, Walmart, Walgreens, and CVS. The company continues to progress with AVERSA Fentanyl development, targeting NDA submission in first half of 2025, requiring only a single phase 1 Human Abuse Potential study.
Market analysis projects potential peak annual sales of $80-$200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine.
Nutriband Inc. (NASDAQ:NTRB) ha riportato risultati finanziari solidi per il terzo trimestre del 2024, con un fatturato record di $645.796, in crescita del 50,94% rispetto all'anno precedente. L'azienda mantiene una solida posizione di liquidità di $5,7 milioni, con attività totali di $12,55 milioni e un patrimonio netto di $11,23 milioni.
Attraverso la sua filiale Pocono Pharma, Nutriband sta espandendo i servizi di produzione di nastro kinesiologico, con prodotti disponibili in importanti rivenditori come Target, Walmart, Walgreens e CVS. L'azienda continua a progredire nello sviluppo di AVERSA Fentanyl, puntando a presentare la NDA nella prima metà del 2025, richiedendo solo uno studio di fase 1 sul potenziale abuso umano.
Le analisi di mercato prevedono vendite annuali potenziali massime di $80-$200 milioni per AVERSA Fentanyl e fino a $130 milioni per AVERSA Buprenorphine.
Nutriband Inc. (NASDAQ:NTRB) informó resultados financieros sólidos para el tercer trimestre de 2024, con ingresos récord de $645,796, un aumento del 50.94% en comparación con el año anterior. La empresa mantiene una sólida posición de efectivo de $5.7 millones, con activos totales de $12.55 millones y un capital contable de $11.23 millones.
A través de su subsidiaria Pocono Pharma, Nutriband está expandiendo sus servicios de fabricación de cinta de kinesiología, con productos disponibles en importantes minoristas como Target, Walmart, Walgreens y CVS. La compañía continúa avanzando en el desarrollo de AVERSA Fentanyl, con el objetivo de presentar la NDA en la primera mitad de 2025, requiriendo solo un estudio de potencial de abuso humano de fase 1.
El análisis de mercado proyecta ventas anuales máximas potenciales de $80-$200 millones para AVERSA Fentanyl y hasta $130 millones para AVERSA Buprenorphine.
Nutriband Inc. (NASDAQ:NTRB)는 2024년 3분기 강력한 재무 결과를 보고했으며, 기록적인 수익인 $645,796를 기록하여 지난해 대비 50.94% 증가했습니다. 이 회사는 570만 달러의 안정적인 현금 보유액을 유지하고 있으며, 총 자산은 1,255만 달러, 주주 자본은 1,123만 달러입니다.
Pocono Pharma 자회사를 통해 Nutriband는 주요 소매업체인 Target, Walmart, Walgreens, CVS에서 제품을 제공하며 운동 생체 역학 테이프 제조 서비스를 확장하고 있습니다. 이 회사는 AVERSA Fentanyl 개발을 지속하고 있으며, 2025년 상반기 NDA 제출을 목표로 하며, 단 하나의 1상 인체 남용 가능성 연구만 필요합니다.
시장 분석에 따르면 AVERSA Fentanyl에 대한 잠재적인 연간 최대 판매는 8천만 달러에서 2억 달러, AVERSA Buprenorphine은 최대 1억 3천만 달러로 예상됩니다.
Nutriband Inc. (NASDAQ:NTRB) a annoncé des résultats financiers solides pour le troisième trimestre 2024, avec un chiffre d'affaires record de 645 796 $, en hausse de 50,94 % par rapport à l'année précédente. La société maintient une solide position de trésorerie de 5,7 millions de dollars, avec des actifs totaux de 12,55 millions de dollars et un capital des actionnaires de 11,23 millions de dollars.
Par l'intermédiaire de sa filiale Pocono Pharma, Nutriband étend ses services de fabrication de tape de kinésiologie, avec des produits disponibles chez des détaillants majeurs tels que Target, Walmart, Walgreens et CVS. L'entreprise continue de progresser dans le développement d'AVERSA Fentanyl, visant à soumettre la NDA au cours du premier semestre 2025, nécessitant seulement une étude de phase 1 sur le potentiel d'abus humain.
Les analyses de marché projettent des ventes annuelles maximales potentielles de 80 à 200 millions de dollars pour AVERSA Fentanyl et jusqu'à 130 millions de dollars pour AVERSA Buprenorphine.
Nutriband Inc. (NASDAQ:NTRB) hat starke Finanzzahlen für das 3. Quartal 2024 berichtet, mit einem Rekordumsatz von 645.796 USD, was einem Anstieg von 50,94 % im Vergleich zum Vorjahr entspricht. Das Unternehmen verfügt über eine solide Liquiditätsposition von 5,7 Millionen USD, insgesamt 12,55 Millionen USD an Vermögenswerten und ein Eigenkapital von 11,23 Millionen USD.
Durch ihre Tochtergesellschaft Pocono Pharma erweitert Nutriband ihre Dienstleistungen zur Herstellung von Kinesiologie-Band, mit Produkten, die in großen Einzelhandelsgeschäften wie Target, Walmart, Walgreens und CVS erhältlich sind. Das Unternehmen schreitet weiterhin mit der Entwicklung von AVERSA Fentanyl voran und plant die Einreichung der NDA in der ersten Hälfte des Jahres 2025, wobei nur eine einzelne Phase-1-Studie zum menschlichen Missbrauchspotenzial erforderlich ist.
Marktanalysen prognostizieren potenzielle jährliche Höchstverkäufe von 80 bis 200 Millionen USD für AVERSA Fentanyl und bis zu 130 Millionen USD für AVERSA Buprenorphin.
- Record Q3 revenue of $645,796, up 50.94% YOY
- Strong cash position of $5.7 million
- Products available in major retail chains
- Simplified regulatory pathway requiring only Phase 1 study
- Potential peak annual sales of $80-$200M for AVERSA Fentanyl
- None.
Insights
The Q3 results demonstrate robust growth with
The streamlined regulatory pathway requiring only a single phase 1 study for NDA submission significantly reduces development costs and time to market. Their contract manufacturing business through Pocono Pharma shows promise with nationwide retail presence in major chains, though penetration pricing strategy may impact near-term margins. The
AVERSA's development pathway represents a significant advantage, bypassing the need for extensive Phase 2 and 3 trials before NDA submission. The focus on abuse-deterrent technology for transdermal opioid delivery addresses a critical market need, particularly given the ongoing opioid crisis. If approved, AVERSA Fentanyl would be the first abuse-deterrent transdermal patch globally, providing a unique market position.
The single Human Abuse Potential study requirement suggests confidence in the technology's core mechanism and safety profile. The expansion into Buprenorphine applications demonstrates platform versatility and potential for multiple product developments. The planned 2025 NDA submission timeline appears realistic given the abbreviated clinical requirements.
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024. The Company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl, with an NDA submission targeted for first half of 2025.
Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary, with a focus on penetration pricing to gain a foothold with some of the industry’s largest brands. The Company produced a record third quarter reporting revenue of
Progress continues on the development of AVERSA Fentanyl, with the Company maintaining its goal of submitting an NDA to the FDA in the first half of 2025. Nutriband recently updated shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a single phase 1 Human Abuse Potential study. Importantly, no Phase 2 or Phase 3 clinical trials will be required before to submission.
If approved, AVERSA Fentanyl could become the first and only abuse-deterrent transdermal patch available globally. AVERSA Fentanyl is estimated to have the potential to reach peak annual sales of
AVERSA Buprenorphine, which is the company’s second application for AVERSA, is projected to reach peak annual sales of up to
As of October 31, 2024, Nutriband's cash reserves stand at
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘’believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Form 10-K for the year ended January 31, 2024, filed May 1, 2024, the Forms 10-Q’s filed subsequent to the Form 10-K in 2024, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
RedChip Companies, Inc.
Email: NTRB@Redchip.com
Phone: 1-407-644-4256
Address:
431 E Horatio Ave, Suite #100
Maitland, FL 32751
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
FAQ
What was Nutriband's (NTRB) revenue growth in Q3 2024?
When does Nutriband (NTRB) plan to submit the NDA for AVERSA Fentanyl?
What are the projected peak annual sales for Nutriband's (NTRB) AVERSA Fentanyl?
What is Nutriband's (NTRB) current cash position as of October 31, 2024?
